FDA ex­perts give a thumbs-up to Aerie Phar­ma’s glau­co­ma drug

Aerie Phar­ma­ceu­ti­cals $AERI ap­pears to be on a glide path to an FDA ap­proval for its glau­co­ma drug Rho­pres­sa.

An ex­pert pan­el con­vened by the FDA of­fered a clear thumbs up, vot­ing 9-1 that the ef­fi­ca­cy of the drug out­weighed any safe­ty risks.

The biotech’s stock slipped 2% af­ter the vote on Fri­day.

That de­ci­sion came on the heels of an in­sid­er FDA re­view that con­clud­ed the drug re­duced el­e­vat­ed in­traoc­u­lar pres­sure in the eye. But the re­view al­so not­ed that the com­para­tor drug, the gener­ic tim­o­lol oph­thalmic so­lu­tion 0.5% twice dai­ly, was more ef­fec­tive for the more se­vere­ly af­flict­ed pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.